MCID: CST005
MIFTS: 53

Castleman Disease

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Castleman Disease

MalaCards integrated aliases for Castleman Disease:

Name: Castleman Disease 12 54 38 56 45 15
Angiofollicular Ganglionic Hyperplasia 54 45 74
Giant Lymph Node Hyperplasia 12 54 17
Angiofollicular Lymph Hyperplasia 12 54
Castleman's Disease 77 15
Angiofollicular Lymph Node Hyperplasia 12
Angiolymphoid Hyperplasia 74
Benign Giant Lymphoma 54
Lymphoid Hamartoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0111157
KEGG 38 H01479
NCIt 51 C3056
SNOMED-CT 69 69484003
ICD10 34 D47.Z2

Summaries for Castleman Disease

NIH Rare Diseases : 54 Castleman disease (CD) is a rare condition that affects the lymph nodes and related tissues. There are two main forms: unicentric CD and multicentric CD. Unicentric CD is a "localized" condition that is generally confined to a single set of lymph nodes, while multicentric CD is a "systemic" disease that affects multiple sets of lymph nodes and other tissues throughout the body. The exact underlying cause of CD is currently unknown; however, it is thought to occur sporadically in people with no family history of the condition. Treatment varies based on the form of the condition, the severity of symptoms and whether or not the affected person also has an HIV and/or human herpes virus type 8 (HHV-8) infection. For more specific information about each form of CD, please visit GARD's unicentric Castleman disease and multicentric Castleman disease pages.

MalaCards based summary : Castleman Disease, also known as angiofollicular ganglionic hyperplasia, is related to multicentric castleman disease and human herpesvirus 8. An important gene associated with Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Valganciclovir and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include lymph node, b cells and t cells, and related phenotypes are immune system and normal

Disease Ontology : 12 A lymphoproliferative syndrome characterized by one or more enlarged lymph nodes containing cells with hyaline-vascular, plasmacytic, or mixed appearance microscopically.

Wikipedia : 77 Castleman disease is a group of uncommon lymphoproliferative disorders characterized by lymph node... more...

Related Diseases for Castleman Disease

Diseases related to Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 358)
# Related Disease Score Top Affiliating Genes
1 multicentric castleman disease 33.2 BCL6 CRP IL10 IL6 PAX5
2 human herpesvirus 8 32.6 BCL6 IL6 IL6R
3 primary effusion lymphoma 30.4 BCL6 IL6 VEGFA
4 pemphigus 30.2 DSG1 DSP EVPL PPL
5 paraneoplastic pemphigus 30.1 DSG1 DSP EVPL PPL
6 hodgkin's lymphoma, lymphocytic-histiocytic predominance 30.1 BCL6 CR2
7 pericardial effusion 30.0 CRP IL6 VEGFA
8 bronchiolitis 29.9 CRP IL10 IL6
9 pneumonia 29.9 CRP IL10 IL6
10 follicular dendritic cell sarcoma 29.7 CR1 CR2 DSP EVPL PPL
11 myeloma, multiple 29.7 CRP IL6 IL6R VEGFA
12 appendicitis 29.6 CRP IL10 IL6
13 lymphoma, non-hodgkin, familial 29.6 BCL6 CR2 IL9 PAX5
14 bronchiolitis obliterans 29.5 EVPL IL10 IL6 PPL
15 acute pancreatitis 29.5 CRP IL10 IL6
16 acquired immunodeficiency syndrome 29.4 BCL6 IL10 IL6
17 hemophagocytic lymphohistiocytosis 29.4 CR1 CR2 IL10
18 rheumatoid arthritis 29.3 CRP IL10 IL6 IL6R VEGFA
19 pemphigus vulgaris 29.3 DSG1 DSP EVPL PPL
20 bullous pemphigoid 29.3 DSG1 DSP EVPL PPL
21 human immunodeficiency virus type 1 29.2 CR1 CR2 IL10 IL6
22 systemic lupus erythematosus 28.9 CR1 CR2 CRP IL10 IL6
23 unicentric castleman disease 12.6
24 pediatric castleman disease 12.3
25 kaposi sarcoma 12.0
26 sarcoma 10.6
27 lymphoma 10.5
28 cold agglutinin disease 10.4 CRP IL6
29 glomerulonephritis 10.4
30 membranoproliferative glomerulonephritis 10.4
31 parapharyngeal meningioma 10.4 CR1 CR2
32 poems syndrome 10.4
33 cryopyrin-associated periodic syndrome 10.4 CRP IL6
34 liver inflammatory pseudotumor 10.4 CR2 CRP
35 interdigitating dendritic cell sarcoma 10.3 CR1 CR2
36 acute cholangitis 10.3 CRP IL6
37 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.3
38 viral pneumonia 10.3 CR1 CRP IL6
39 uremic pruritus 10.3 CRP IL6
40 langerhans cell sarcoma 10.3 CR1 CR2
41 preterm premature rupture of the membranes 10.3 CRP IL6 IL6R
42 critical limb ischemia 10.3 IL6 VEGFA
43 t-cell/histiocyte rich large b cell lymphoma 10.2 BCL6 CR1 CR2
44 amyloidosis 10.2
45 tafro syndrome 10.2
46 bullous impetigo 10.2 DSG1 IL6
47 impetigo 10.2 DSG1 IL6
48 neutrophilia, hereditary 10.2 CRP IL6
49 spinal disease 10.2 CRP IL6 VEGFA
50 intermittent claudication 10.2 CRP IL6 VEGFA

Graphical network of the top 20 diseases related to Castleman Disease:



Diseases related to Castleman Disease

Symptoms & Phenotypes for Castleman Disease

MGI Mouse Phenotypes related to Castleman Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.61 BCL6 CR2 CRP IL10 IL6 IL6R
2 normal MP:0002873 9.17 BCL6 IL10 IL6R IL9 PAX5 PPL

Drugs & Therapeutics for Castleman Disease

Drugs for Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
2 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Early Phase 1
3 Antiviral Agents Phase 4,Phase 2,Early Phase 1
4 Siltuximab Approved, Investigational Phase 2,Phase 1,Early Phase 1 541502-14-1
5
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
6
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
7
Zidovudine Approved Phase 2 30516-87-1 35370
8
Lenograstim Approved, Investigational Phase 2 135968-09-1
9
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
10
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
11
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
12
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
13
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
14
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
15
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
16
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
17
Everolimus Approved Phase 2,Phase 1 159351-69-6 70789204 6442177
18
Pomalidomide Approved Phase 1, Phase 2 19171-19-8
19
Suramin Investigational Phase 2 145-63-1 5361
20
Doxil Approved June 1999 Phase 2,Phase 1 31703
21 Histamine Antagonists Phase 2
22 Analgesics Phase 2
23 Histamine H1 Antagonists Phase 2
24 Immunoglobulins Phase 2,Phase 1,Early Phase 1
25 Immunologic Factors Phase 2,Phase 1,Early Phase 1
26 Antipyretics Phase 2
27 Antibodies Phase 2,Phase 1,Early Phase 1
28 Antibodies, Monoclonal Phase 2,Phase 1,Early Phase 1
29 Pharmaceutical Solutions Phase 2,Phase 1
30 Antiprotozoal Agents Phase 2
31 Antiparasitic Agents Phase 2
32 Anthelmintics Phase 2
33 Hormone Antagonists Phase 2,Phase 1
34 Antineoplastic Agents, Hormonal Phase 2,Phase 1
35 Hormones Phase 2,Phase 1
36 glucocorticoids Phase 2,Phase 1
37 Angiogenesis Inhibitors Phase 2,Phase 1
38 Alkylating Agents Phase 2,Phase 1
39 Antirheumatic Agents Phase 2,Phase 1
40 Immunosuppressive Agents Phase 2,Phase 1
41 Anti-Inflammatory Agents Phase 2,Phase 1
42 Angiogenesis Modulating Agents Phase 2,Phase 1
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
44 Anti-Bacterial Agents Phase 2,Phase 1
45 Antineoplastic Agents, Alkylating Phase 2,Phase 1
46 Antimetabolites Phase 2,Phase 1
47 Anti-Retroviral Agents Phase 2,Early Phase 1
48 Anti-HIV Agents Phase 2,Early Phase 1
49 Reverse Transcriptase Inhibitors Phase 2
50 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4 Valganciclovir
2 A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Completed NCT01024036 Phase 2 Siltuximab;Placebo;Best Supportive Care (BSC)
3 A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Completed NCT01400503 Phase 2 Siltuximab
4 Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease Completed NCT00002652 Phase 2 suramin
5 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
6 TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Recruiting NCT03043105 Phase 2 Thalidomide, cyclophosphamide and prednisone
7 Tocilizumab for KSHV-Associated Multicentric Castleman Disease Recruiting NCT01441063 Phase 2 Zidovudine;Tocilizumab;Valganciclovir (VGC)
8 Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Recruiting NCT00092222 Phase 2 Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
9 Siltuximab in Schizophrenia Recruiting NCT02796859 Phase 1, Phase 2 Siltuximab;normal saline
10 Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease Not yet recruiting NCT03933904 Phase 2 Sirolimus
11 Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy Terminated NCT00127569 Phase 2 Rituximab
12 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
13 Dose-escalation Study of Oral CX-4945 Unknown status NCT00891280 Phase 1 CX-4945 oral formulation
14 A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment Completed NCT01183598 Phase 1 tocilizumab [RoActemra/Actemra]
15 A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease Completed NCT00412321 Phase 1 CNTO 328
16 An Open-Label Trial of Tocilizumab in Schizophrenia Completed NCT01696929 Phase 1 Tocilizumab
17 Tocilizumab in Schizophrenia Recruiting NCT02874573 Phase 1 Tocilizumab;Normal saline
18 Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma Recruiting NCT02659930 Phase 1 liposomal doxorubicin;pomalidomide
19 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
20 Rituximab Hyaluronidase and Combination Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda Not yet recruiting NCT03864419 Phase 1 Cyclophosphamide;Vincristine;Methotrexate;Doxorubicin;Doxorubicin Hydrochloride;Prednisone;Etoposide
21 Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Terminated NCT02109224 Phase 1 Ibrutinib
22 Epithelioid Hemangioma of Bone And Soft Tissue Completed NCT03169595
23 Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Completed NCT00695422
24 International Registry for Patients With Castleman Disease Recruiting NCT02817997
25 Unlock the Cell: Castleman's Disease Flow Cytometry Study Recruiting NCT02853968
26 Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease Recruiting NCT03300830
27 Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Recruiting NCT00006518
28 Registry for Adults With Plasma Cell Disorders (PCD's) Recruiting NCT03717844
29 Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors Terminated NCT02080416 Early Phase 1 Nelfinavir
30 Castleman Disease Collaborative Network Biobank Withdrawn NCT02871050
31 Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Withdrawn NCT02805868 Early Phase 1

Search NIH Clinical Center for Castleman Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: castleman disease

Genetic Tests for Castleman Disease

Anatomical Context for Castleman Disease

MalaCards organs/tissues related to Castleman Disease:

42
Lymph Node, B Cells, T Cells, Bone, Lung, Prostate, Liver

Publications for Castleman Disease

Articles related to Castleman Disease:

(show top 50) (show all 559)
# Title Authors Year
1
Rheumatoid arthritis-like active synovitis with T-cell activation in a case of idiopathic multicentric Castleman disease: A case report. ( 31045763 )
2019
2
Amyloidosis secondary to intrapulmonary Castleman disease mimicking pulmonary hyalinizing granuloma-like clinical features: A rare case report. ( 30946344 )
2019
3
Hyaline vascular-type unicentric Castleman disease presenting as a subcutaneous nodule in a child. ( 30156317 )
2019
4
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. ( 30203839 )
2019
5
A prospective description of HIV-associated multicentric Castleman disease in Malawi. ( 30442726 )
2019
6
Spontaneous middle lobe torsion in a patient with multicentric Castleman disease: A case report. ( 30467976 )
2019
7
Concomitant perinephric Castleman disease and renal cell carcinoma initially suspected to be metastasis: A case report and 24 months follow up. ( 30479965 )
2019
8
Radiologic and Histopathologic Features in an Intracranial Localized Castleman Disease: A Case Report and Review of Literature. ( 30586033 )
2019
9
Recurrent PDGFRB mutations in unicentric Castleman disease. ( 30607019 )
2019
10
Tuberculous lymphadenitis mimicking Castleman disease-like histological features. ( 30632056 )
2019
11
Tufted angioma-like lesion associated with VEGF and IL-6 in TAFRO syndrome: Is it a common histological feature of multicentric Castleman disease/POEMS syndrome? ( 30632181 )
2019
12
An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome. ( 30642741 )
2019
13
Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study. ( 30680887 )
2019
14
Castleman disease presenting with jaundice: A case report and review of literature. ( 30746379 )
2019
15
Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. ( 30760451 )
2019
16
A Case of Castleman Disease With Recurrence in the Neck: Case Report and Literature Review. ( 30825440 )
2019
17
Development of Castleman Disease in the Paravertebral Space Mimicking a Neurogenic Tumor. ( 30834220 )
2019
18
Unusual case of human herpesvirus 8-positive large B-cell lymphoma associated with Castleman disease. ( 30899504 )
2019
19
Castleman Disease in a Patient with Common Variable Immunodeficiency. ( 30906603 )
2019
20
Successful treatment of a child with idiopathic multicentric Castleman disease associated with hemophagocytic lymphohistiocytosis using tocilizumab. ( 30989798 )
2019
21
Castleman Disease Presenting as a Supraclavicular Neck Mass in a Child. ( 30991840 )
2019
22
Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases. ( 31016730 )
2019
23
Castleman Disease Masquerading as the Posterior Mediastinal Mass on 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography. ( 31040538 )
2019
24
Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
. ( 29701172 )
2018
25
Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease? ( 28401573 )
2018
26
Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan. ( 28880697 )
2018
27
Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients. ( 29124835 )
2018
28
Castleman disease: delineating the spectrum. ( 29143317 )
2018
29
The full spectrum of Castleman disease: 273 patients studied over 20 years. ( 29143319 )
2018
30
Epidemiology of Castleman Disease. ( 29157611 )
2018
31
Castleman Disease Pathogenesis. ( 29157613 )
2018
32
The Peripheral Neuropathies of POEMS Syndrome and Castleman Disease. ( 29157616 )
2018
33
The Role of Interleukin-6 in Castleman Disease. ( 29157617 )
2018
34
Pathology of Castleman Disease. ( 29157618 )
2018
35
Diagnosis of Castleman Disease. ( 29157619 )
2018
36
Unicentric Castleman Disease. ( 29157620 )
2018
37
Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. ( 29157621 )
2018
38
Treatment of Idiopathic Castleman Disease. ( 29157622 )
2018
39
Castleman Disease. ( 29157623 )
2018
40
EBV+ HHV-8+ Multicentric Castleman Disease With Plasmablastic Aggregates in an HIV+ Man: An Evolving Clinicopathologic Entity. ( 29198143 )
2018
41
Castleman Disease and Rosai-Dorfman Disease. ( 29217303 )
2018
42
Plasma Cell Variant Multicentric Castleman Disease and Kaposi's Sarcoma in a Treatment-Naive HIV-Infected Patient. ( 29345958 )
2018
43
Successful use of rituximab in glomerular basement membrane nephritis associated with HIV interstitial nephritis secondary to Castleman disease
. ( 29424337 )
2018
44
Tocilizumab Cannot Prevent the Development of Bronchiolitis Obliterans in Patients With Castleman Disease-Associated Paraneoplastic Pemphigus. ( 29389687 )
2018
45
Unicentric castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus. ( 30128272 )
2018
46
Indolent T-lymphoblastic proliferation associated with low grade follicular dendritic cell sarcoma and Castleman disease. ( 29486963 )
2018
47
Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. ( 29496669 )
2018
48
The Clinical and Immunologic Features of Patients With Combined Anti-GBM Disease and Castleman Disease. ( 29510921 )
2018
49
Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease. ( 29557805 )
2018
50
Castleman disease in the hilum liver mimicking the lymph node metastasis of hepatocellular carcinoma on 18F-FDG PET/CT: A case report. ( 29561464 )
2018

Variations for Castleman Disease

Expression for Castleman Disease

Search GEO for disease gene expression data for Castleman Disease.

Pathways for Castleman Disease

Pathways related to Castleman Disease according to KEGG:

38
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 JAK-STAT signaling pathway hsa04630
3 Hematopoietic cell lineage hsa04640

Pathways related to Castleman Disease according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 BCL6 CR1 CRP DSG1 DSP IL10
2
Show member pathways
13.13 BCL6 IL10 IL6 IL6R IL9 VEGFA
3
Show member pathways
12.14 IL10 IL6 IL6R IL9
4
Show member pathways
12.11 DSG1 DSP EVPL KRT15 PPL
5
Show member pathways
11.9 BCL6 IL10 IL6
6
Show member pathways
11.88 CR1 CR2 CRP
7 11.88 IL10 IL6 IL6R VEGFA
8
Show member pathways
11.85 IL10 IL6 IL6R
9
Show member pathways
11.84 IL10 IL6 IL6R IL9
10
Show member pathways
11.72 DSP EVPL PPL
11 11.67 IL6 IL6R VEGFA
12 11.66 IL10 IL6 IL6R
13 11.44 CR1 CR2 IL6 IL6R
14 11.41 BCL6 IL10 IL6 IL6R VEGFA
15 11.34 IL6 IL6R VEGFA
16 11.3 CR1 IL10 IL6
17 11.26 IL6 IL6R VEGFA
18 10.85 CRP IL6
19 10.75 BCL6 CR2 IL10 IL6R PAX5

GO Terms for Castleman Disease

Cellular components related to Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.56 DSP EVPL KRT15 PPL
2 ficolin-1-rich granule membrane GO:0101003 9.5 CR1 DSG1 DSP
3 cornified envelope GO:0001533 9.26 DSG1 DSP EVPL PPL
4 interleukin-6 receptor complex GO:0005896 9.16 IL6 IL6R
5 desmosome GO:0030057 8.92 DSG1 DSP EVPL PPL

Biological processes related to Castleman Disease according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.85 IL10 IL6 IL6R IL9 VEGFA
2 inflammatory response GO:0006954 9.8 BCL6 CRP IL10 IL6 IL9
3 epidermis development GO:0008544 9.75 DSP EVPL KRT15
4 wound healing GO:0042060 9.73 DSP EVPL PPL
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 IL6 IL6R VEGFA
6 B cell differentiation GO:0030183 9.67 BCL6 CR2 IL10
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 IL6 IL6R VEGFA
8 cytokine-mediated signaling pathway GO:0019221 9.65 BCL6 IL10 IL6 IL6R VEGFA
9 positive regulation of chemokine production GO:0032722 9.59 IL6 IL6R
10 interleukin-6-mediated signaling pathway GO:0070102 9.58 IL6 IL6R
11 complement receptor mediated signaling pathway GO:0002430 9.57 CR1 CR2
12 positive regulation of leukocyte chemotaxis GO:0002690 9.55 IL6 IL6R
13 acute-phase response GO:0006953 9.54 CRP IL6 IL6R
14 positive regulation of cellular component movement GO:0051272 9.52 BCL6 VEGFA
15 negative regulation of lipid storage GO:0010888 9.51 CRP IL6
16 type 2 immune response GO:0042092 9.43 BCL6 IL10
17 keratinization GO:0031424 9.35 DSG1 DSP EVPL KRT15 PPL
18 intermediate filament cytoskeleton organization GO:0045104 9.33 DSP EVPL PPL
19 hepatic immune response GO:0002384 9.32 IL6 IL6R
20 cornification GO:0070268 9.02 DSG1 DSP EVPL KRT15 PPL

Molecular functions related to Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of cytoskeleton GO:0005200 9.43 DSP KRT15 PPL
2 cytokine activity GO:0005125 9.26 IL10 IL6 IL9 VEGFA
3 interleukin-6 receptor binding GO:0005138 9.16 IL6 IL6R
4 growth factor activity GO:0008083 9.02 IL10 IL6 IL6R IL9 VEGFA

Sources for Castleman Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....